178 related articles for article (PubMed ID: 27106017)
1. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
[TBL] [Abstract][Full Text] [Related]
2. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
5. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
Chappell NP; Miller CR; Fielden AD; Barnett JC
J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
Case AS; Rocconi RP; Partridge EE; Straughn JM
Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
[TBL] [Abstract][Full Text] [Related]
11. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
[TBL] [Abstract][Full Text] [Related]
12. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Havrilesky LJ; Secord AA; Kulasingam S; Myers E
Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Fisher M; Gore M
Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
17. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
19. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL; Meisner BC; Frick KD; Armstrong DK
Cancer; 2007 Apr; 109(8):1513-22. PubMed ID: 17354232
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
